Appointments of new CEO, CFO, and seasoned business development leaders with proven track records of executing strategic transactions will position the Company to drive shareholder value and advance p ...

Research and development collaboration program to include additional models of lymphoma and leukemia to further validate ...

A team of Memorial Sloan Kettering Cancer Center (MSK) researchers have made an important finding about why genetically ...

The UK is the first country to introduce a dedicated law to decentralise manufacturing of personalised medicines at the point ...

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the United States by 2030, it ...

From cell-manufacturing laboratories to outpatient infusion facilities, health systems are rapidly adapting to a new kind of cancer treatment that demands individualized care, infrastructure and ...

AstraZeneca Plc. announced on Monday that it plans to invest $50 billion in the U.S. by 2030, with a focus on expanding drug ...

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...

Amid a season of regulatory and scientific advances, experts reveal a culture of data hoarding among cell and gene therapy ...

Iovance Biotherapeutics, Inc. stock faces challenges with disappointing Q1 earnings and competition. Click for why potential ...

Discover how Genome Valley is emerging as an essential partner in global biopharma and how it is now venturing into cell and ...